SCHEMBL23809253

SCHEMBL23809253

CC(C)c1ccc(C(=O)O)c2ncccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.54
L3MBTL1 Q9Y468 4/20 0.54
KDM4A O75164 2/20 0.54
EGLN1 Q9GZT9 2/20 0.54
KDM6B O15054 1/20 0.54
KDM6A O15550 1/20 0.54
TET3 O43151 1/20 0.54
KDM4B O94953 1/20 0.54
KDM5C P41229 1/20 0.54
KDM4D Q6B0I6 1/20 0.54
TET2 Q6N021 1/20 0.54
ALKBH5 Q6P6C2 1/20 0.54
TET1 Q8NFU7 1/20 0.54
FTO Q9C0B1 1/20 0.54
KDM4C Q9H3R0 1/20 0.54
KDM2A Q9Y2K7 1/20 0.54
KDM3A Q9Y4C1 1/20 0.54
ACE2 Q9BYF1 1/20 0.48
ALDH1A1 P00352 2/20 0.46
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23809130 0.88 KDM4E (0.50) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL26551421 0.88 KDM4E (0.62) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL345151 0.85 KDM4E (0.49) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL69673 0.81 KDM4E (0.77) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL31499282 0.80 ACE2 (0.45) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL11321990 0.79 L3MBTL1 (0.48) KDM4EL3MBTL1TDP1RAB9ASLC40A1
SCHEMBL11803761 0.79 SLC6A2 (0.59) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL30503371 0.79 SLC6A2 (0.59) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL2586914 0.78 KDM4E (0.50) KDM4EL3MBTL1KDM4AEGLN1KDM6B
SCHEMBL27575501 0.78 SLC6A2 (0.57) KDM4EL3MBTL1KDM4AEGLN1KDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331710-A1 HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) 2023-10-19 US disclosed
US-20230331710-A1 HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) 2023-10-19 US disclosed
US-20210283138-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2021-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331710-A1 HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF C9, CFB, C5 KDM4E 3798/4885L3MBTL1 4732/4885KDM4A 4275/4885
US-20210283138-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 KDM4E 1156/4885L3MBTL1 135/4885KDM4A 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.